DEB-TACE: Clinical Trials

7 trials of DEB-TACE, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 27Recruiting 2, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1

Follow DEB-TACE: new trials by email Literature Review of DEB-TACE trials Research Report on DEB-TACE

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
DEB-TACE, Toripalimab, Lenvatinib - Liver Cancer
Phase 2Not yet recruitingShanghai Zhongshan Hospital292026-06-302026-07-06
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Lenvatinib, Pembrolizumab, Atezolizumab - HCC - Hepatocellular Carcinoma
Phase 2RecruitingPeking Union Medical College Hospital3002025-02-192025-12-01
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
DEB-TACE+HAIC, DEB-TACE - Hepatocellular Carcinoma Non-resectable
Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical University1302024-05-012025-02-20
Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
DEB-TACE, Lenvatinib plus pucotenlimab - Cholangiocarcinoma Non-resectable
Phase 2UnknownTongji Hospital362023-12-092024-01-09
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Tremelimumab, Durvalumab, Y-90 SIRT - Hepatocellular Carcinoma Non-resectable, HCC
Phase 2Active not recruitingInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest552020-12-152026-06-23
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
Sintilimab, DEB-TACE - Hepatocellular Carcinoma
Phase 2UnknownZhejiang University612019-11-202022-06-09
Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)
Trans-arterial Chemo-Embolization, Doxorubicin, Stereotactic Ablative Radiotherapy - Liver Neoplasms, Hepatocellular Cancer
Phase 2TerminatedCliniques universitaires Saint-Luc- Université Catholique de Louvain32017-02-202017-11-07

Conditions studied

Carcinoma, Hepatocellular (4)  ·  Liver Neoplasms (2)  ·  Cholangiocarcinoma (1)

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1)  ·  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)  ·  Peking Union Medical College Hospital (1)  ·  Second Affiliated Hospital of Guangzhou Medical University (1)  ·  Shanghai Zhongshan Hospital (1)  ·  Tongji Hospital (1)  ·  Zhejiang University (1)

Countries

China (4)  ·  Belgium (1)  ·  Germany (1)

Top investigators

Arndt Vogel, Prof. Dr. (1)  ·  Salah-Eddin Al-Batran, Prof. Dr. (1)  ·  Ze-yang Ding, M.D. (1)

Results publications

PMID 36757445

NIH funding

2019 (1)